Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that triggers coronavirus disease 2019 (COVID-19). This latest SARS disease was first identified during an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China. The World Health Organization first declared this to be a global health emergency in January 2020. By March, COVID-19 rocketed to a global pandemic—the first such designation since 2009’s H1N1 influenza pandemic.
As of mid-March 2020, global confirmed cases of COVID-19 have surpassed 184,000 with over 7,400 deaths worldwide. While there are fewer new cases in China, containment efforts have so far failed to reduce the rate of reported cases in many countries. The virus is continuing its global spread with the distinct possibility of becoming a new endemic coronavirus within the human population.
As an active supporter of the scientific community that is collaborating today on COVID-19 solutions, BIOVIA, Dassault Systèmes is proud to offer BIOVIA Discovery Studio. This world-class life sciences modeling and simulation environment brings together over 30 years of peer-reviewed research and world-class in silico techniques. It provides researchers with a complete toolset for use from target identification through to lead optimization, including tools for biologics design and analysis, classical simulations, structure- and fragment-based design, virtual ligand screening, as well as ADME and toxicity prediction.
As part of Dassault Systèmes’ corporate social responsibility, BIOVIA is pleased to offer academic researchers six months of complimentary access to BIOVIA Discovery Studio to assist them in the search for rapid, safe and effective therapeutic drug candidates against the SARS-CoV-2 virus. If you are an academic researcher in this field, please submit the form for review in order to arrange a software license and download.
Also, Follow BIOVIA on LinkedIn for upcoming blog posts on other topics pertaining to BIOVIA Discovery Studio’s usefulness in COVID-19 research, including protein structure determination with homology modeling, virtual screening/drug repurposing and pharmacophore modeling for lead identification.